Malaria kills nearly 600,000 people every year, the majority of whom are children under the age of five in sub-Saharan Africa. The need to develop an effective vaccine against the disease has long been a top priority — but given the highly complex life cycle of the parasite, characterisation of key elements that correlate with protective immunity has been very difficult. After decades of slow progress, there seems to be light at the end of the long tunnel. WHO approval in October 2021 for RTS,S/AS01 (Mosquirix) developed by GlaxoSmithKline for immunising children was a major milestone. View More